Portland Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History

Portland Investment Counsel’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$505K	Buy	+654	New	+$501K	0.16%	43
2024 Q4	–	Sell	-324	Closed	-$341K	–	57
2024 Q3	$341K	Hold	324	–	–	0.12%	42
2024 Q2	$341K	Sell	324 -3	-0.9%	-$2.91K	0.12%	43
2024 Q1	$315	Hold	327	–	–	0.09%	40
2023 Q4	$287K	Hold	327	–	–	0.1%	33
2023 Q3	$269K	Sell	327 -3	-0.9%	-$2.36K	0.12%	32
2023 Q2	$237K	Hold	330	–	–	0.12%	35
2023 Q1	$271K	Hold	330	–	–	0.12%	32
2022 Q4	$238K	Hold	330	–	–	0.14%	32
2022 Q3	$227K	Buy	+330	New	+$208K	0.15%	32
2022 Q2	–	Sell	-330	Closed	-$230K	–	37
2022 Q1	$230K	Buy	330 +1	+0.3%	+$633	0.12%	33
2021 Q4	$208K	Buy	+329	New	+$202K	0.09%	36

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Portland Investment Counsel's REGN Position: Q1 2026 in Review

Portland Investment Counsel opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 654 shares worth $505K. The stake represents 0.16% of the portfolio and ranks #43 among its holdings. This is a return to the name: Portland Investment Counsel previously reported a position in REGN as recently as Q3 2024.

Portland Investment Counsel first reported a position in REGN in Q4 2021 and has held it in 12 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Portland Investment Counsel held 654 shares of Regeneron Pharmaceuticals worth $505K as of Q1 2026.
Regeneron Pharmaceuticals was a new Portland Investment Counsel position in Q1 2026.
Regeneron Pharmaceuticals made up 0.16% of Portland Investment Counsel's portfolio in Q1 2026, its #43 holding.
Portland Investment Counsel first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Portland Investment Counsel's 13F filing for Q1 2026, filed 14 May 2026.